A recent study has stated that Alzheimer’s drug Leqembi can slow the progression of Alzheimer disease for over 3 years.
About Leqembi:
- Drug Type: Monoclonal antibody
- Mechanism: Targets and removes beta-amyloid plaques from the brain, a hallmark of Alzheimer’s disease.
- Administration: Currently an intravenous (IV) infusion, twice a month.
- The drug provides a potentially valuable option for managing Alzheimer’s disease during its early stages.
About Alzheimer Disease:
- The most common type of dementia, characterized by progressive memory loss and cognitive decline.
- Onset: Symptoms typically appear after age 60, with risk increasing with age.
Ref: Source
| UPSC IAS Preparation Resources | |
| Current Affairs Analysis | Topperspedia |
| GS Shots | Simply Explained |
| Daily Flash Cards | Daily Quiz |
Frequently Asked Question:
What is the primary target of the drug Leqembi in the treatment of Alzheimer’s disease?
The primary target of Leqembi is beta-amyloid plaques in the brain.
What is the mechanism of action of the Alzheimer’s drug Leqembi?
Leqembi works by targeting and removing beta-amyloid plaques from the brain, which are a hallmark of Alzheimer’s disease.
At what age do symptoms of Alzheimer’s disease typically begin to appear?
Symptoms of Alzheimer’s disease typically appear after age 60.
Which type of drug is Leqembi classified as, and what is its method of administration?
Leqembi is classified as a monoclonal antibody and is administered as an intravenous (IV) infusion, twice a month.
Identify the most common type of dementia characterized by progressive memory loss and cognitive decline.
Alzheimer’s disease is the most common type of dementia, characterized by progressive memory loss and cognitive decline.